JavaScript is disabled for your browser. Some features of this site may not work without it.
RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model
Ignatoski, Kathleen M. Woods; Escara-Wilke, J. F.; Dai, J. -L.; Lui, A.; Dougall, W.; Daignault, S.; Yao, Z.; Zhang, J.; Day, M. L.; Sargent, E. E.; Keller, E. T.
Ignatoski, Kathleen M. Woods; Escara-Wilke, J. F.; Dai, J. -L.; Lui, A.; Dougall, W.; Daignault, S.; Yao, Z.; Zhang, J.; Day, M. L.; Sargent, E. E.; Keller, E. T.
2008-06-01
Citation:Ignatoski, K. M. Woods; Escara-Wilke, J. F.; Dai, J.-L.; Lui, A.; Dougall, W.; Daignault, S.; Yao, Z.; Zhang, J.; Day, M. L.; Sargent, E. E.; Keller, E. T. (2008). "RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model." The Prostate 68(8): 820-829. <http://hdl.handle.net/2027.42/58561>